ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,354.05
0.49%
Dow Jones
39,014.36
0.33%
Gold vs US Dollar
2,313.245
-0.08%
Brent Oil
83.365
0.60%
Bitcoin
62,662.89
0.53%
Pepperstone
Advertisement
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. Europe
  5. EU
  6. Pharming Group NV (PHARM)

  7. Pharming Group NV (PHARM) News

Pharming Group NV (PHARM)

Pharming Group NV
Date:
Sort by:
 Showing the most relevant articles for your search:EU:PHARM
DateTimeSourceHeadlineSymbolCompany
08/05/202406:00GlobeNewswire Inc.Pharming Group reports first quarter 2024 financial results and provides business updateEU:PHARMPharming Group NV
08/05/202406:00GlobeNewswire Inc.Pharming Group reports first quarter 2024 financial results and provides business updateEU:PHARMPharming Group NV
24/04/202407:00GlobeNewswire Inc.Pharming Group to report first quarter 2024 financial results on May 8EU:PHARMPharming Group NV
24/04/202406:00GlobeNewswire Inc.Pharming to be honored as Industry Innovator at National Organization for Rare Disorders (NORD®) 2024 Rare Impact AwardsEU:PHARMPharming Group NV
24/04/202406:00GlobeNewswire Inc.Pharming to be honored as Industry Innovator at National Organization for Rare Disorders (NORD®) 2024 Rare Impact AwardsEU:PHARMPharming Group NV
19/04/202417:43GlobeNewswire Inc.Pharming Group announces the repurchase of outstanding €125 million convertible bonds due 2025EU:PHARMPharming Group NV
18/04/202414:04GlobeNewswire Inc.Pharming Group announces the placement of €100 million convertible bonds due 2029EU:PHARMPharming Group NV
18/04/202407:00GlobeNewswire Inc.Pharming Group announces the launch of an offering of approximately €100 million convertible bonds due 2029 and the concurrent repurchase of the outstanding €125 million convertible bonds due 2025EU:PHARMPharming Group NV
08/04/202406:00GlobeNewswire Inc.Pharming announces completion of enrollment in pediatric clinical trial of leniolisibEU:PHARMPharming Group NV
08/04/202406:00GlobeNewswire Inc.Pharming announces completion of enrollment in pediatric clinical trial of leniolisibEU:PHARMPharming Group NV
04/04/202407:30GlobeNewswire Inc.Pharming Group announces the 2024 Annual General Meeting of ShareholdersEU:PHARMPharming Group NV
04/04/202406:00GlobeNewswire Inc.Pharming Group announces the filing of its 2023 Annual Report and Form 20-FEU:PHARMPharming Group NV
03/04/202407:00GlobeNewswire Inc.Pharming Group to participate in April investor conferencesEU:PHARMPharming Group NV
03/04/202407:00GlobeNewswire Inc.Pharming Group to participate in April investor conferencesEU:PHARMPharming Group NV
14/03/202406:00GlobeNewswire Inc.Pharming Group reports fourth quarter and full year 2023 financial resultsEU:PHARMPharming Group NV
29/02/202407:00GlobeNewswire Inc.Pharming Group to report fourth quarter and full year 2023 financial results on March 14EU:PHARMPharming Group NV
29/02/202407:00GlobeNewswire Inc.Pharming Group to report fourth quarter and full year 2023 financial results on March 14EU:PHARMPharming Group NV
08/02/202407:00GlobeNewswire Inc.Pharming Group to participate in February investor conferencesEU:PHARMPharming Group NV
08/02/202407:00GlobeNewswire Inc.Pharming Group to participate in February investor conferencesEU:PHARMPharming Group NV
08/01/202406:00GlobeNewswire Inc.Pharming Group announces updated full year 2023 guidance and Joenja® U.S. launch updateEU:PHARMPharming Group NV
08/01/202406:00GlobeNewswire Inc.Pharming Group announces updated full year 2023 guidance and Joenja® U.S. launch updateEU:PHARMPharming Group NV
13/12/202306:00GlobeNewswire Inc.Pharming Group announces development plans for leniolisib for additional primary immunodeficiencies (PIDs)EU:PHARMPharming Group NV
21/11/202306:00GlobeNewswire Inc.Pharming announces first patient dosed in pediatric clinical trial for children aged 1 to 6 years for leniolisibEU:PHARMPharming Group NV
21/11/202306:00GlobeNewswire Inc.Pharming announces first patient dosed in pediatric clinical trial for children aged 1 to 6 years for leniolisibEU:PHARMPharming Group NV
10/11/202313:51GlobeNewswire Inc.Pharming Group provides updates on EMA regulatory review of leniolisib MAA and plans to file for UK regulatory approvalEU:PHARMPharming Group NV
01/11/202307:00GlobeNewswire Inc.Pharming Group to participate in November investor conferencesEU:PHARMPharming Group NV
01/11/202307:00GlobeNewswire Inc.Pharming Group to participate in November investor conferencesEU:PHARMPharming Group NV
26/10/202306:00GlobeNewswire Inc.Pharming Group reports third quarter 2023 financial resultsEU:PHARMPharming Group NV
12/10/202307:00GlobeNewswire Inc.Pharming Group to report third quarter 2023 financial results on October 26EU:PHARMPharming Group NV
12/10/202307:00GlobeNewswire Inc.Pharming Group to report third quarter 2023 financial results on October 26EU:PHARMPharming Group NV
 Showing the most relevant articles for your search:EU:PHARM

Your Recent History

LSE
BOO
Boohoo
LSE
POS
Plexus
LSE
CHLL
Chill Brands
LSE
AAZ
Anglo Asian Mining
LSE
RR.
Rolls-royce
LSE
VAST
Vast Resources
LSE
CSFS
Cornerstone Fs
LSE
AGL
Angle
LSE
PET
Petrel Resources
LSE
GCM
Gcm Resources
LSE
APH
Alliance Pharma
LSE
BARC
Barclays
LSE
KEFI
Kefi Gold And Copper
LSE
TERN
Tern
LSE
SYME
Supply@me Capital
LSE
SCLP
Scancell
Delayed Upgrade Clock
    ADVFN Logo

    United Kingdom
    Company
    Business
    Popular
    Get The App

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved